Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online June 7, 2019.
Article Versions
- Latest version (March 15, 2019 - 04:00).
- You are currently viewing a Latest version of this article (June 7, 2019 - 08:30).
- latest version (August 1, 2019 - 04:00).
- View the most recent version of this article
Copyright & Usage
© 2019 The Journal of Rheumatology
Author Information
- Laure Gossec,
- Vibeke Strand,
- Clare Proudfoot,
- Chieh-I Chen,
- Sophie Guillonneau,
- Toshio Kimura,
- Hubert van Hoogstraten,
- Erin Mangan and
- Matthew Reaney
- From the Sorbonne Université and Rheumatology Department, Hôpital; Stanford University; Novartis; Regeneron Pharmaceuticals, Inc and Sanofi.
L. Gossec has acted as a consultant for Abbvie, BMS, Celgene, Janssen, Lilly, Novartis, MSD, Pfizer, Roche, Sanofi and UCB. V. Strand has acted as a consultant for AbbVie, Amgen, AstraZeneca, Biogen, BMS, Celgene, Celltrion, Consortium of Rheumatology Researchers of North America (CORRONA), Crescendo/Myriad Genetics, Genentech/Roche, GSK, Janssen, Eli Lilly, Novartis, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sandoz, Sanofi, and UCB. C. Proudfoot is a former employee of and current shareholder in Sanofi and current employee and shareholder of ViiV Healthcare/GlaxoSmithKline. C. Chen, T. Kimura, and E. Mangan are employees of and shareholders in Regeneron Pharmaceuticals, Inc. E. Mangan is also a shareholder in Pfizer. S. Guillonneau, H. van Hoogstraten, and M. Reaney are employees of and hold shares or options in Sanofi.
Address correspondence to Matthew Reaney, Sanofi, One Onslow Street, Guildford, Surrey, GU1 4YS, UK. E-mail: matthew.reaney@sanofi.com